The prognostic value of miR-34 family in ovarian cancer: a systematic review and meta-analysis.

Abstract

<h4>Background</h4>The aim of this study was to evaluate the association between miR-34 family expression and overall survival (OS) and progression-free survival (PFS) in women with ovarian cancer.<h4>Methods</h4>Literature searches were conducted using databases such as PubMed, Cochrane Library, EMBASE, Web of Science, Wanfang, and CNKI to identify studies reporting pooled hazard ratios (HRs) and 95% confidence intervals (CIs) examining the relationship between miR-34 family expression and overall survival (OS) or progression-free survival (PFS) in female patients with ovarian cancer. All potentially relevant studies were assessed and then pooled.<h4>Results</h4>There were a total of seven literatures included in this systematic review and meta-analysis, which included 672 women. There was a significant improvement in survival for women with ovarian cancer when miR-34s expression was higher (OS, HR = 0.70, 95% CI:0.57-0.86; PFS, HR = 0.48, 95% CI:0.31-0.75). A subgroup analysis of miR-34 family members showed that differences between groups greatly affected PFS (HR = 0.50, 95% CI: 0.40-0.63).<h4>Conclusion</h4>Based on the results of this review, it appears that ovarian cancer women with high expression of miR-34s may have a better chance of surviving.Systematic Review Registration: PROSPERO (CRD42024499203).<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024499203.